Silexion Therapeutics CORP (SLXNW) — S-1 Filings
All S-1 filings from Silexion Therapeutics CORP. Browse 3 IPO Filing reports with AI-powered summaries and risk analysis.
S-1 Filings (3)
-
Silexion Launches Best-Efforts Offering Amidst Reverse Splits
— Sep 5, 2025 Risk: high
Silexion Therapeutics Corp (SLXNW) is conducting a best-efforts offering of up to 832,177 ordinary shares, accompanied by Series A and Series B ordinary warrant -
Silexion Files S-1 for Resale of 314,859 Shares Amidst Funding Needs
— Aug 26, 2025 Risk: high
Silexion Therapeutics Corp (SLXNW) is a clinical-stage oncology biotechnology company focused on developing RNA-interference therapeutics for KRAS-driven cancer -
Silexion Therapeutics Files S-1
— Feb 12, 2025 Risk: medium
Silexion Therapeutics Corp. filed an S-1 form on February 12, 2025, detailing its business operations. The company, formerly known as Biomotion Sciences until a
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX